PF-739是一种AMPK激活剂，通过激活12种异三聚体AMPK复合物来降低血浆葡萄糖水平。
Cas No.:1852452-14-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
PF-739 is an AMPK activator. PF-739 reduces plasma glucose levels by activating all 12 heterotrimeric AMPK complexes. PF-739 can be used in research related to type 2 diabetes and metabolic syndrome[1-2].
In vitro, PF-739 (0-10µM) treatment of hepatocytes and skeletal muscle myotubes. PF-739 increased phosphorylation of Acetyl-CoA carboxylase (ACC) and inhibition of de novo lipogenesis in hepatocytes[3]. PF-739 (10µM) treatment of isolated mouse extensor digitorum longus (EDL) and soleus muscle fibers for 30 minutes. PF-739 significantly increased glucose uptake and promoted glycogen accumulation[4].
In vivo, PF-739 (10-300mg/kg; orally, 30-100mg/kg; subcutaneously) treatment of diet-induced obese (DIO) mice and db/db diabetic mice rapidly lowered blood glucose levels within 1-6 hours after administration. PF-739 increased the whole-body glucose disposal rate and enhanced glycogen synthesis, labeling of glycolytic intermediates, and mitochondrial content in skeletal muscle[3]. A single subcutaneous injection of PF-739 (100mg/kg) in diet-induced obese wild-type and inducible skeletal muscle-specific AMPK α1/α2 knockout mice. PF-739 significantly increased the glucose disposal rate and lowered blood glucose in wild-type mice, an effect that was absent in AMPK knockout mice[4].
References:
[1] Weihrauch M, Handschin C. Pharmacological targeting of exercise adaptations in skeletal muscle: Benefits and pitfalls. Biochem Pharmacol. 2018 Jan;147:211-220.
[2] Aledavood E, Gheeraert A, Forte A, et al. Elucidating the Activation Mechanism of AMPK by Direct Pan-Activator PF-739. Front Mol Biosci. 2021 Nov 5;8:760026.
[3] Cokorinos EC, Delmore J, Reyes AR, et al. Activation of Skeletal Muscle AMPK Promotes Glucose Disposal and Glucose Lowering in Non-human Primates and Mice. Cell Metab. 2017 May 2;25(5):1147-1159.e10.
[4] Esquejo RM, Albuquerque B, Sher A, et al. AMPK activation is sufficient to increase skeletal muscle glucose uptake and glycogen synthesis but is not required for contraction-mediated increases in glucose metabolism. Heliyon. 2022 Oct 14;8(10):e11091.
PF-739是一种AMPK激活剂，通过激活12种异三聚体AMPK复合物来降低血浆葡萄糖水平。PF-739可用于2型糖尿病和代谢综合征的相关研究[1-2]。
在体外，PF-739（0-10µM）处理肝细胞及骨骼肌肌管细胞，导致乙酰辅酶A羧化酶（ACC）磷酸化增加，并抑制肝细胞新生脂肪生成[3]。PF-739（10µM）处理小鼠离体伸趾长肌（EDL）及比目鱼肌纤维30分钟，显著增加其葡萄糖摄取，同时促进糖原积累[4]。
在体内，PF-739（10-300mg/kg；口服，30-100mg/kg；皮下注射）处理饮食诱导肥胖（DIO）小鼠、db/db糖尿病小鼠。PF-739在给药后1-6小时内可快速降低血糖水平，PF-739可增加全身葡萄糖处置率，并在骨骼肌中增加糖原合成、糖酵解中间产物的标记以及线粒体含量[3]。PF-739（100mg/kg）单次皮下注射于饮食诱导肥胖的野生型及可诱导骨骼肌特异性AMPK α1/α2敲除小鼠。PF-739显著增加了野生型小鼠的葡萄糖处理率并降低了血糖，且此效应在AMPK敲除小鼠中消失[4]。
| Cell experiment [1]: | |
Cell lines | Rat hepatocytes and human skeletal muscle myotubes |
Preparation Method | Rat hepatocytes were isolated from Sprague Dawley rats and plated in Williams E Media. Human skeletal muscle myotubes were maintained in growth media and differentiated for 48 hours in differentiation media at 37°C, 5% CO₂. Cell was treated with PF-739 at concentrations of 0-10µM |
Reaction Conditions | 0-10µM; 0.5-1h. |
Applications | PF-739 treatment significantly increased phosphorylation of Acetyl-CoA Carboxylase (ACC) at Ser79 in hepatocytes and at Ser212 in skeletal muscle myotubes, indicating AMPK activation. In hepatocytes, PF-739 also inhibited de novo lipogenesis with an IC₅₀ of 25nM. |
| Animal experiment [2]: | |
Animal models | C57BL/6 mice (wild-type and inducible skeletal muscle AMPK α1/α2 knockout mice on C57Bl/6J background) |
Preparation Method | Diet-induced obese (DIO) wild-type and knockout mice were subjected to hyperinsulinemic-hyperglycemic clamp studies. Mice were subcutaneously administered vehicle or PF-739 (100mg/kg) following the start of insulin infusion, and blood glucose was clamped to hyperglycemic levels. |
Dosage form | 100mg/kg; s.c.; single injection. |
Applications | PF-739 administration reduced blood glucose by increasing the glucose disposal rate (Rd) in an AMPK-dependent manner. This glucose-lowering effect was absent in skeletal muscle-specific AMPK knockout mice, confirming skeletal muscle as the primary site of action. Additionally, ex vivo studies showed that PF-739 treatment increased glycogen content in skeletal muscle. |
References: | |
| Cas No. | 1852452-14-2 | SDF | |
| 分子式 | C23H23ClN2O5 | 分子量 | 442.89 |
| 溶解度 | DMSO : 100 mg/mL (225.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2579 mL | 11.2895 mL | 22.579 mL |
| 5 mM | 451.6 μL | 2.2579 mL | 4.5158 mL |
| 10 mM | 225.8 μL | 1.1289 mL | 2.2579 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet